14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PRME vs VTYX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Prime Medicine, Inc. (PRME) on higher Unified Composite conviction (50.4/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality), while PRME wins 3–1 across the 6-pillar growth and valuation breakdown. PRME trades at $4.24 (N/M Forward P/E, -4824.9% operating margin) versus VTYX at $14.00 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While PRME currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4824.9% operating margin) and revenue trajectory (+0.0% vs. +3.5% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRME vs VTYX. Trailing 12-month operating profitability (PRME -4824.9% vs VTYX 0.0%) and valuation multiples (PRME N/M vs VTYX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PRME vs VTYX Key Questions & Quantitative Answers
As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Prime Medicine, Inc. (PRME) on higher Unified Composite conviction (50.4/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality), while PRME wins 3–1 across the 6-pillar growth and valuation breakdown. PRME trades at $4.24 (N/M Forward P/E, -4824.9% operating margin) versus VTYX at $14.00 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PRME currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4824.9% operating margin) and revenue trajectory (+0.0% vs. +3.5% YoY).
PRME leads the Growth & Scale pillar: PRME posts +3.5% YoY revenue growth and +0.0% YoY earnings growth on $4.1M TTM revenue (N/A gross margin, -4824.9% operating margin), compared with VTYX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PRME generates $4.1M in USD-normalized revenue versus N/A for VTYX. In operating R&D and SG&A reinvestment, PRME deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTYX.
PRME and VTYX trade at balanced relative valuation multiples. PRME trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRME (-373.3% ROE) versus VTYX (-45.4% ROE) capital efficiency.
In options market volatility and institutional positioning, PRME carries 139.6% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (2.44β · 149% Vol realized risk). By comparison, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.